Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned an average rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.00.

A number of equities analysts have issued reports on CLBT shares. Bank of America increased their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 15th. Lake Street Capital lifted their target price on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Needham & Company LLC upped their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Greenhaven Road Investment Management L.P. lifted its position in shares of Cellebrite DI by 8.9% in the third quarter. Greenhaven Road Investment Management L.P. now owns 1,653,047 shares of the company’s stock valued at $30,631,000 after buying an additional 135,000 shares during the last quarter. Connors Investor Services Inc. increased its holdings in shares of Cellebrite DI by 36.3% during the 3rd quarter. Connors Investor Services Inc. now owns 245,789 shares of the company’s stock worth $4,554,000 after acquiring an additional 65,479 shares during the last quarter. Advisory Services Network LLC bought a new stake in Cellebrite DI in the 3rd quarter valued at $40,000. Oberweis Asset Management Inc. lifted its holdings in Cellebrite DI by 4.7% during the 3rd quarter. Oberweis Asset Management Inc. now owns 414,550 shares of the company’s stock valued at $7,682,000 after purchasing an additional 18,580 shares during the last quarter. Finally, Virtus Advisers LLC boosted its position in Cellebrite DI by 297.7% during the third quarter. Virtus Advisers LLC now owns 12,954 shares of the company’s stock worth $240,000 after purchasing an additional 9,697 shares during the period. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $19.24 on Tuesday. The business’s 50-day simple moving average is $17.72 and its 200-day simple moving average is $16.66. Cellebrite DI has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The stock has a market capitalization of $4.61 billion, a PE ratio of 62.06, a price-to-earnings-growth ratio of 3.28 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The company had revenue of $126.03 million for the quarter, compared to analyst estimates of $122.98 million. During the same quarter last year, the business posted $0.14 earnings per share. The business’s quarterly revenue was up 17.9% on a year-over-year basis. On average, research analysts expect that Cellebrite DI will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.